ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 50,000 Shares

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total transaction of $710,000.00. Following the sale, the insider now owns 604,205 shares of the company’s stock, valued at approximately $8,579,711. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Jaume Pons also recently made the following trade(s):

• On Thursday, April 4th, Jaume Pons sold 20,000 shares of ALX Oncology stock. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00.

ALX Oncology Stock Performance

Shares of NASDAQ:ALXO traded down $0.34 during midday trading on Thursday, hitting $15.74. The stock had a trading volume of 667,307 shares, compared to its average volume of 434,640. The company has a market capitalization of $789.36 million, a PE ratio of -4.29 and a beta of 1.58. ALX Oncology Holdings Inc. has a 1 year low of $3.94 and a 1 year high of $17.42. The stock has a 50 day moving average price of $13.52 and a two-hundred day moving average price of $11.87. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.05.

ALX Oncology (NASDAQ:ALXO) last released its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.09). As a group, equities analysts predict that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on ALXO. Stifel Nicolaus reissued a “hold” rating and issued a $14.00 target price (up from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of ALX Oncology in a research note on Wednesday, April 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, ALX Oncology has an average rating of “Moderate Buy” and an average price target of $18.83.

Institutional Trading of ALX Oncology

A number of institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in ALX Oncology in the fourth quarter valued at about $28,000. Royal Bank of Canada raised its holdings in ALX Oncology by 226.6% during the second quarter. Royal Bank of Canada now owns 4,001 shares of the company’s stock worth $30,000 after purchasing an additional 2,776 shares during the last quarter. Legal & General Group Plc boosted its position in ALX Oncology by 42.6% during the fourth quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock worth $34,000 after purchasing an additional 684 shares in the last quarter. UBS Group AG grew its holdings in ALX Oncology by 38.7% in the first quarter. UBS Group AG now owns 10,043 shares of the company’s stock valued at $45,000 after purchasing an additional 2,801 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in ALX Oncology in the third quarter valued at $48,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.